Literature DB >> 28421428

How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities.

Katherine M Tyner1, Nan Zheng1, Stephanie Choi1, Xiaoming Xu1, Peng Zou1, Wenlei Jiang1, Changning Guo1, Celia N Cruz2.   

Abstract

The Nanotechnology Risk Assessment Working Group in the Center for Drug Evaluation and Research (CDER) within the United States Food and Drug Administration (FDA) was established to assess the potential impact of nanotechnology on drug products. One of the working group's major initiatives has been to conduct a comprehensive risk management exercise regarding the potential impact of nanomaterial pharmaceutical ingredients and excipients on drug product quality, safety, and efficacy. This exercise concluded that current review practices and regulatory guidance are capable of detecting and managing the potential risks to quality, safety, and efficacy when a drug product incorporates a nanomaterial. However, three risk management areas were identified for continued focus during the review of drug products containing nanomaterials: (1) the understanding of how to perform the characterization of nanomaterial properties and the analytical methods used for this characterization, (2) the adequacy of in vitro tests to evaluate drug product performance for drug products containing nanomaterials, and (3) the understanding of properties arising from nanomaterials that may result in different toxicity and biodistribution profiles for drug products containing nanomaterials. CDER continues to actively track the incorporation of nanomaterials in drug products and the methodologies used to characterize them, in order to continuously improve the readiness of our science- and risk-based review approaches. In parallel to the risk management exercise, CDER has also been supporting regulatory research in the area of nanotechnology, specifically focused on characterization, safety, and equivalence (between reference and new product) considerations. This article provides a comprehensive summary of regulatory and research efforts supported by CDER in the area of drug products containing nanomaterials and other activities supporting the development of this emerging technology.

Entities:  

Keywords:  CDER; nanomaterials; nanotechnology; risk assessment; risk management

Mesh:

Year:  2017        PMID: 28421428     DOI: 10.1208/s12248-017-0084-6

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  41 in total

Review 1.  Pharmacokinetics and in vivo drug release rates in liposomal nanocarrier development.

Authors:  Daryl C Drummond; Charles O Noble; Mark E Hayes; John W Park; Dmitri B Kirpotin
Journal:  J Pharm Sci       Date:  2008-11       Impact factor: 3.534

2.  Molecular weight determination for colloidal iron by Taguchi optimized validated gel permeation chromatography.

Authors:  R B Shah; Y Yang; M A Khan; P J Faustino
Journal:  Int J Pharm       Date:  2007-11-22       Impact factor: 5.875

3.  In Vitro and In Vivo Performance of Different Sized Spray-Dried Crystalline Itraconazole.

Authors:  Sumit Kumar; Rajan Jog; Jie Shen; Banu Zolnik; Nakissa Sadrieh; Diane J Burgess
Journal:  J Pharm Sci       Date:  2014-09-05       Impact factor: 3.534

4.  The state of nano-sized titanium dioxide (TiO2) may affect sunscreen performance.

Authors:  K M Tyner; A M Wokovich; D E Godar; W H Doub; N Sadrieh
Journal:  Int J Cosmet Sci       Date:  2011-01-25       Impact factor: 2.970

5.  Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.

Authors:  Jeremy A Bartlett; Marcus Brewster; Paul Brown; Donna Cabral-Lilly; Celia N Cruz; Raymond David; W Mark Eickhoff; Sabine Haubenreisser; Abigail Jacobs; Frank Malinoski; Elaine Morefield; Ritu Nalubola; Robert K Prud'homme; Nakissa Sadrieh; Christie M Sayes; Hripsime Shahbazian; Nanda Subbarao; Lawrence Tamarkin; Katherine Tyner; Rajendra Uppoor; Margaret Whittaker-Caulk; William Zamboni
Journal:  AAPS J       Date:  2014-11-25       Impact factor: 4.009

6.  A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation, processing design and risk assessment.

Authors:  Xiaoming Xu; Mansoor A Khan; Diane J Burgess
Journal:  Int J Pharm       Date:  2011-07-19       Impact factor: 5.875

7.  Quality by design: understanding the formulation variables of a cyclosporine A self-nanoemulsified drug delivery systems by Box-Behnken design and desirability function.

Authors:  Ahmed S Zidan; Omaima A Sammour; Mohammed A Hammad; Nagia A Megrab; Muhammad J Habib; Mansoor A Khan
Journal:  Int J Pharm       Date:  2006-10-21       Impact factor: 5.875

Review 8.  Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats.

Authors:  Michelle Longmire; Peter L Choyke; Hisataka Kobayashi
Journal:  Nanomedicine (Lond)       Date:  2008-10       Impact factor: 5.307

9.  Particle size determination of sunscreens formulated with various forms of titanium dioxide.

Authors:  Anna Wokovich; Katherine Tyner; William Doub; Nakissa Sadrieh; Lucinda F Buhse
Journal:  Drug Dev Ind Pharm       Date:  2009-10       Impact factor: 3.225

10.  siRNA-containing liposomes modified with polyarginine effectively silence the targeted gene.

Authors:  Chunling Zhang; Ning Tang; XingJun Liu; Wei Liang; Wei Xu; Vladimir P Torchilin
Journal:  J Control Release       Date:  2006-03-20       Impact factor: 9.776

View more
  4 in total

Review 1.  Subchronic and chronic toxicity evaluation of inorganic nanoparticles for delivery applications.

Authors:  Raziye Mohammadpour; Marina A Dobrovolskaia; Darwin L Cheney; Khaled F Greish; Hamidreza Ghandehari
Journal:  Adv Drug Deliv Rev       Date:  2019-07-08       Impact factor: 15.470

Review 2.  Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval.

Authors:  Duhyeong Hwang; Jacob D Ramsey; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2020-09-24       Impact factor: 15.470

Review 3.  Critical review of nucleic acid nanotechnology to identify gaps and inform a strategy for accelerated clinical translation.

Authors:  Kirill A Afonin; Marina A Dobrovolskaia; Weina Ke; Piotr Grodzinski; Mark Bathe
Journal:  Adv Drug Deliv Rev       Date:  2021-12-13       Impact factor: 17.873

Review 4.  Opportunities and challenges for the clinical translation of structured DNA assemblies as gene therapeutic delivery and vaccine vectors.

Authors:  Marina A Dobrovolskaia; Mark Bathe
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-07-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.